Evidence map›Paper›PMID 29351794›Full record

ArticleCardiovascular diabetology2018

Metabolic syndrome severity is significantly associated with future coronary heart disease in Type 2 diabetes.

Matthew J Gurka, Yi Guo, Stephanie L Filipp, Mark D DeBoer

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular diabetology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 5 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 5 syntheses or guidelines pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Matthew J GurkaDepartment of Health Outcomes and Policy, College of Medicine, University of Florida, Gainesville, FL, 32608, USA.
Yi GuoDepartment of Health Outcomes and Policy, College of Medicine, University of Florida, Gainesville, FL, 32608, USA.
Stephanie L FilippDepartment of Health Outcomes and Policy, College of Medicine, University of Florida, Gainesville, FL, 32608, USA.
Mark D DeBoerDepartment of Pediatrics, Division of Pediatric Endocrinology, University of Virginia, 409 Lane Rd, Room 2017, P.O. Box 800386, Charlottesville, VA, 22908, USA. deboer@virginia.edu.
University of Florida · USUniversity of Virginia · US

Funding

Socioeconomic Status and Subjective Social Status as Modifiers of Stressors and Discrimination in their Relationship with MetS Severity Over TimeR01HL120960 · NHLBI · WEST VIRGINIA UNIVERSITY · PI DEBOER, MARK DANIEL, GURKA, MATTHEW JAMES · 2014 to 2018
$2.1M
National Heart, Lung, and Blood Institute (US) 1R01HL120960NHLBI NIH HHS HHSN268201000021CNHLBI NIH HHS HHSN268201700001INHLBI NIH HHS HHSN268201700002INHLBI NIH HHS HHSN268201700003INHLBI NIH HHS HHSN268201700004INHLBI NIH HHS HHSN268201700005INHLBI NIH HHS R01 HL120960
6 · The paper itself

Abstract

backgroundThe severity of the metabolic syndrome (MetS) is significantly associated with future coronary heart disease (CHD) among individuals without baseline Type 2 diabetes. However, the validity of assessing MetS severity among individuals with diabetes is unknown.

objectiveTo assess for differences in MetS severity by timing of Type 2 diabetes diagnosis and to assess for associations between MetS severity and future CHD among individuals with diabetes.

methodsWe analyzed data from participants of the Atherosclerosis Risk in Communities study, including 1419 with- and 7241 without diabetes, followed during 4 visits and adjudicated CHD diagnoses over a 20-year period. We used Cox-regression techniques to assess hazard ratios (HR) of CHD based on a sex- and race/ethnicity-specific MetS-severity Z-score (standard MetS score) and a similar MetS-severity score formulated without incorporating glucose as a component of MetS (no-glucose MetS score).

resultsFor both the standard- and no-glucose MetS-severity scores, scores were highest in the baseline-diabetes group, lowest in the never-diabetes group and intermediate in the incident-diabetes groups. Among participants with diabetes, increasing MetS-severity score at baseline was associated with incident CHD, using both the standard MetS score (HR 1.29, 95% confidence interval [CI] 1.21, 1.39) and the no-glucose score (HR 1.42, CI 1.24, 1.62) (both p < 0.001). For the baseline-diabetes group, this relationship remained significant when Visit 2 Hemoglobin-A

conclusionsMetS severity appears to provide an estimate of metabolic disarray in the setting of diabetes and is predictive of future CHD events beyond HbA1c. Identifying MetS severity among individuals with diabetes may help in identifying those at higher risk, who could then receive further preventative treatment.

Indexed as

BiomarkersBlood GlucoseBlood PressureCoronary DiseaseDiabetes Mellitus, Type 2Disease ProgressionFemaleGlycated HemoglobinHumansLipidsMaleMetabolic SyndromeMiddle AgedPrognosisRisk AssessmentRisk FactorsBiomarkersBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanLipidsCardiovascular diseaseDiabetesMetabolic syndromeRisk

Identifiers

PMID29351794
PMCPMC5775549
OpenAlexW2790986958

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.